GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading MASH threads from 2024 and half of it aged badly — 48 comments in the full submission. View in context.
3.5k
c/survodutide·submitted 1 year ago by u/nora_ramos

reading MASH threads from 2024 and half of it aged badly

Trial Databranch of 7 comments

reading MASH threads from 2024 and half of it aged badly. It is the sort of thing everyone half-believes and nobody writes down. Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both…

Read the full submission and all 48 comments →

This branch

7 comments, started 1 year ago
u/employer_carveout112 points·1 year ago

Looked for independent results across this whole site and found almost none. Worth knowing before forming an opinion.

replysharereportpermalink
u/zeynep_ndiaye26 points·1 year ago

a liver endpoint is not a weight endpoint with better marketing

replysharereportpermalink
u/zeynep_ndiaye14 points·1 year ago

Correcting myself: the readout I quoted was the 45-week interim rather than the endpoint.

replysharereportpermalink
u/dexa_twice_yearlybody comp11 points·1 year ago

Right, and the trial titration was slow for reasons that are visible in the tolerability tables.

replysharereportpermalink
u/samir_falk3 points·1 year ago

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

replysharereportpermalink
u/rafael_sjoberg6 points·1 year ago

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

replysharereportpermalink
u/meera_sandvik18 points·1 year ago

not approved anywhere, and the boards forget that constantly

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →